Spyre Therapeutics annual debt-to-equity ratio
2019
2020
2021
2022
2023
2024
2025
Spyre Therapeutics Debt-to-Equity Ratio Growth & History (SYRE)
Spyre Therapeutics's debt-to-equity ratio was 0.00 for fiscal 2025.
View full Spyre Therapeutics company overviewSpyre Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.00 | 0.00 | — |
| 2024 | 2024-12-31 | 0.00 | 0.00 | — |
| 2023 | 2023-12-31 | 0.00 | −0.09 | — |
| 2022 | 2022-12-31 | 0.09 | 0.03 | +41.49% |
| 2021 | 2021-12-31 | 0.07 | 0.03 | +65.32% |
| 2020 | 2020-12-31 | 0.04 | −0.05 | −53.69% |
| 2019 | 2019-12-31 | 0.09 | — | — |
Spyre Therapeutics quarterly debt-to-equity ratio
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.00 | 0.00 | — |
| Q1 2026 | 2026-03-31 | 0.00 | 0.00 | — |
| Q4 2025 | 2025-12-31 | 0.00 | 0.00 | — |
| Q3 2025 | 2025-09-30 | 0.00 | 0.00 | — |
| Q2 2025 | 2025-06-30 | 0.00 | 0.00 | — |
| Q1 2025 | 2025-03-31 | 0.00 | 0.00 | — |
| Q4 2024 | 2024-12-31 | 0.00 | 0.00 | — |
| Q3 2024 | 2024-09-30 | 0.00 | — | — |
| Q2 2024 | 2024-06-30 | 0.00 | — | — |
| Q1 2024 | 2024-03-31 | 0.00 | −0.13 | — |
| Q4 2023 | 2023-12-31 | 0.00 | −0.09 | — |
| Q1 2023 | 2023-03-31 | 0.13 | 0.05 | +64.88% |
| Q4 2022 | 2022-12-31 | 0.09 | 0.03 | +41.49% |
| Q3 2022 | 2022-09-30 | 0.07 | 0.02 | +38.96% |
| Q2 2022 | 2022-06-30 | 0.06 | 0.01 | +28.09% |
| Q1 2022 | 2022-03-31 | 0.08 | 0.04 | +85.64% |
| Q4 2021 | 2021-12-31 | 0.07 | 0.03 | +65.32% |
| Q3 2021 | 2021-09-30 | 0.05 | 0.01 | +30.29% |
| Q2 2021 | 2021-06-30 | 0.04 | 0.01 | +37.51% |
| Q1 2021 | 2021-03-31 | 0.04 | −0.08 | −63.95% |
| Q4 2020 | 2020-12-31 | 0.04 | −0.05 | −53.69% |
| Q3 2020 | 2020-09-30 | 0.04 | −0.03 | −40.71% |
| Q2 2020 | 2020-06-30 | 0.03 | −0.02 | −38.24% |
| Q1 2020 | 2020-03-31 | 0.12 | 0.11 | +1709.25% |
| Q4 2019 | 2019-12-31 | 0.09 | — | — |
| Q3 2019 | 2019-09-30 | 0.07 | — | — |
| Q2 2019 | 2019-06-30 | 0.05 | — | — |
| Q1 2019 | 2019-03-31 | 0.01 | — | — |
Spyre Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Spyre Therapeutics's debt-to-equity ratio decreased from 0.04 to 0.00, a change of −0.04. The latest reported quarter, Q2 2026, shows 0.00.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Spyre Therapeutics source filings ↗